News & Events

Entry into a Material Definitive Agreement. On April 28, 2026 (the “Effective Date”), SAB Biotherapeutics, Inc., a Delaware corporation (the “Company” or “SAB BIO”) entered into a Master Manufacturing Services Agreement (the “MSA”) with Emergent BioSolutions Canada Inc. (“Emergent”). Pursuant to the MSA, Emergent will perform clinical and commercial manufacturing and related services for the Company with respect to SAB-142 (the “Product”) at Emergent’s facility in Canada. The MSA commences on…

Regulation FD Disclosure. On April 22, 2026, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company” or “SAB BIO”) made available a presentation that includes additional information regarding the Company’s Phase 1 HUman anti-thymocyte biologic in first-in-MAN (HUMAN) clinical trial of SAB-142 (the “Presentation”). On April 22, 2026, the Company also issued a press release announcing the release of the data set forth in the Presentation (the “Release”). A copy of the Release is furnis…

Entry into a Material Definitive Agreement. On March 17, 2026, SAB Biotherapeutics, Inc. (the “Company” or “SAB”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, UBS Securities LLC, Citigroup Capital Markets, Inc. and Barclays Capital Inc. (collectively, the “Representatives”) as the representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten offering (the “Offering”) of (i) 19,324,677 shares (the “Firm…

Other Events. On March 10, 2026, the Company announced additional data from its Phase 1 HUman anti-thymocyte biologic in first-in-MAN (HUMAN) clinical trial of SAB-142. In the trial, the established T1D adult patient cohort demonstrated early signals of C-peptide preservation aligned with the anticipated mechanism of action of SAB-142. In the T1D cohort (n=6), SAB-142 treated study participants (n=4) showed no decrease in C-peptide levels at Day 120 compared to baseline. The placebo study par…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 5, 2026, the Board of Directors (the “Board”) of SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed, David Zaccardelli, Pharm.D, and Rita Jain, M.D. each to serve as a Class II director of the Company, effective Janua…

Other Events. Establishment of “At the Market Offering” Program On December 29, 2025, SAB Biotherapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “ Agreement ” ) with UBS Securities LLC (the “Agent”) with respect to an at-the-market offering program under which the Company may offer and sell from time to time through or to the Agent, as sales agent or principal, the Company’s common stock, par value $0.0001 per share, having an aggregate offering price of up to $75,000,000 (…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 30, 2025, Christine Hamilton and Jeffrey Spragens resigned as members of the Board of Directors (the “Board”) of SAB Biotherapeutics, Inc. (the “Company”) and the size of the Board was decreased from 11 to nine, in accordance with the terms of the letter agreement entered into between the Company and RA Capital Healthcare Fund, L.P., d…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 26, 2025, SAB Biotherapeutics, Inc. (the “Company” or “SAB”), held a special meeting of stockholders (the “Special Meeting”). At the Special Meeting, the Company’s stockholders approved an amendment (the “Plan Amendment”) to the Company’s 2021 Omnibus Equity Incentive Plan, as amended (the “Plan”) to, among other things, (i) increase t…

Entry into a Material Definitive Agreement. Securities Purchase Agreement On July 21, 2025, SAB Biotherapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Offering ”), (i) 1,000,000 shares (the “ Shares ”) of the Company’s newly-designated Series B Convertible Preferred Stock, par value $0…

The Shares and Warrants are being sold and, upon exercise the securities underlying the Warrants and conversion of the Preferred Shares, will be issued without registration under the Securities Act, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.

Other Events. Press Releases Related to Offering On July 21, 2025 the Company issued a press release announcing the entry into the Offering, a copy of which is attached hereto as Exhibit 99.1, and incorporated by reference herein. FDA On May 29th, 2025, the Company held a constructive Type B meeting with the U.S. Food and Drug Administration (the “ FDA ”). The meeting followed positive topline data from a Phase 1 single-ascending dose trial in healthy volunteers for SAB-142. The primary discu…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information included in

Entry into a Material Definitive Agreement. On January 30, 2025, SAB Biotherapeutics, Inc. (the “Company”) entered into a lease agreement, dated and effective February 1, 2025 (the “Sanford Lease Agreement”), with Sanford Health, a South Dakota non-profit corporation ( the “Landlord”). The Sanford Lease Agreement provides for a lease area of 21,014 from the Landlord to the Company, located at 2301 East 60th Street North, Sioux Falls, South Dakota 57104. Annual rent payable under the Sanford L…